Metropolis Healthcare has allotted 15,54,95,826 equity shares of face value of Rs 2/- each as fully paid equity shares, in the ratio of 3:1, to the eligible members of the Company whose names appeared in the Register of Members / Register of the Beneficial Owners, as on 20 March 2026, the `Record Date` fixed for this purpose. Consequent to the aforesaid allotment, paid-up share capital of the Company stands increased to Rs 41,46,55,536/- divided into 20,73,27,768 equity shares of face value of Rs 2/- each.Powered by Capital Market - Live News

Net profit of Metropolis Healthcare rose 31.98% to Rs 41.39 crore in the quarter ended December 2025 as against Rs 31.36 crore during the previous quarter ended December 2024. Sales rose 25.76% to Rs 405.91 crore in the quarter ended December 2025 as against Rs 322.77 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales405.91322.77 26 OPM %23.3722.31 - PBDT98.1470.03 40 PBT66.2642.34 56 NP41.3931.36 32 Powered by Capital Market - Live News

Metropolis Healthcare will hold a meeting of the Board of Directors of the Company on 4 February 2026.Powered by Capital Market - Live News

Metropolis Healthcare has allotted 9,960 equity shares under the Metropolis - Restrictive Stock Unit Plan, 2020 on 13 January 2026. Powered by Capital Market - Live News

Metropolis Healthcare announced the launch of its Centre of Genomics, marking a significant step in scaling its long standing capabilities in advanced genomics, molecular diagnostics, precision medicine, and genomic research. The Centre of Genomics is designed to deliver clinically actionable genomic insights across the care continuum, supporting multiple high-impact clinical specialties. Over the years, Metropolis has built a strong foundation in advanced genomics, with a particular focus on precision oncology anchored by its Global Reference Laboratory in Mumbai. Following the integration of Core Diagnostics` specialised genomics laboratory in the Delhi NCR region, these complementary capabilities have been unified to operate as CAP-accredited national referral laboratories for genomics, forming the backbone of the Centre of Genomics. This integrated model brings together a broad portfolio of NGS-based assays, robust bioinformatics and interpretation capabilities, and deep scientific and clinical expertise.As part of the Centre`s technology backbone, Metropolis has augmented its existing sequencing infrastructure with the deployment of Illumina`s NovaSeq� X Series for research purposes. The NovaSeq� X system features Illumina`s cutting-edge XLEAP-SBS� chemistry, offering unmatched throughput, accuracy, and sustainability. The NovaSeq� X Plus can generate more than 20,000 whole genomes per year, more than double the throughput of Illumina`s previous sequencers. Its unprecedented speed, scale, and accuracy push the limits of what is possible in genetic sequencing, enabling users to unlock discoveries and advancements that were previously beyond reach.Beyond the newly deployed NovaSeq� X Series, the Centre of Genomics is supported by an existing, multi-platform NGS infrastructure already operational across Metropolis` key genomics hubs. The Centre of Genomics brings together multidisciplinary teams of molecular pathologists, genomic scientists, researchers, bioinformaticians, and certified genetic counsellors to ensure that complex genomic data is translated into clear, reliable, and clinically meaningful insights for patient care.Powered by Capital Market - Live News